JP2000063250A - Composition for oral cavity - Google Patents

Abstract

PROBLEM TO BE SOLVED: To obtain a composition for oral cavity excellent in dental plaque formation-suppressing effect and having high commercial value by including a copolymer of vinylpyrrolidone with vinyl acetate as a dental plaque formation suppressant. SOLUTION: A copolymer of (A) vinylpyrrolidone with (B) vinyl acetate is included as a dental plaque formation-suppressing agent to provide the objective composition. The molar ratio of components A/B is preferably (5/5) to (6/4). The average molecular weight of the copolymer is preferably 10,000-100,000 based on weight-average molecular weight. The content of the copolymer is preferably 0.01-2 wt.% based on the composition. An abrasive (e.g. sedimentary silica), a viscolizer (e.g. carboxymethylcellulose sodium), a surface active agent (e.g. sodium lauryl sulfate), a sweetening agent (e.g. saccharin sodium), etc., are compounded in the case of dentifrice such as tooth paste in the composition.

Description

Description: TECHNICAL FIELD [0001] The present invention relates to an oral composition having a high plaque formation inhibitory effect. [0002] Hitherto, it has been known that dextranase, alkyloyl sarcosinate and the like have a plaque-inhibiting effect, and compositions containing these (Japanese Patent No. 78215)
4, JP-A-54-20142, JP-A-62-195
No. 320) has been proposed. However, there is still room for study on the plaque-suppressing effects of the above-mentioned dextranase and alkyloyl sarcosinate, and there is a need for the development of a composition for oral cavity with further enhanced effects. [0003] It is an object of the present invention to provide an oral composition having an excellent plaque formation inhibitory effect. The present inventors have conducted intensive studies to solve the above-mentioned problems, and as a result, the copolymer of vinylpyrrolidone and vinyl acetate has a high plaque formation inhibitory effect. And found that the present invention was completed. That is, according to the present invention, there is provided an oral composition comprising a copolymer of vinylpyrrolidone and vinyl acetate as a plaque formation inhibitor. DETAILED DESCRIPTION OF THE INVENTION In the present invention, a copolymer of vinylpyrrolidone and vinyl acetate is used as a plaque formation inhibitor to be incorporated into an oral composition. In this copolymer, the molar ratio [A] / [B] of the content [A] of the vinylpyrrolidone component and the content [B] of the vinyl acetate component is not particularly limited, but is preferably 2/8 or more. It is preferable to set the ratio to 7/3, more preferably 5/5 to 6/4. The average molecular weight of the copolymer is 1,0 by weight average molecular weight.
00 to 1,000,000, preferably 10,000 to
100,000. The copolymer is water and alcohol-
Soluble in water. These copolymers have already been sold and are available as Luviskol VA series from BASF and Kolidon VA series. The composition for the oral cavity of the present invention contains the copolymer, and the content thereof is 0.001 to 0.001 in the composition.
It is 5% by weight, preferably 0.01 to 2% by weight. If the content is less than the above range, the effect of the addition may be insufficient. On the other hand, if the content is more than the above range, the composition may have an unpleasant taste. [0006] In addition to the copolymer, the oral composition of the present invention is blended with appropriate conventional components according to the specific type of the composition. For example, in the case of toothpastes such as toothpaste, abrasives, thickeners, binders, surfactants, sweeteners, flavors, coloring agents, preservatives, active ingredients, and the like are blended. These components are blended in an amount in the range generally applied conventionally.
Examples of the abrasive include silica-based abrasives such as precipitated silica, silica gel, aluminosilicate, and zirconosilicate; dibasic calcium phosphate dihydrate and anhydride; calcium pyrophosphate; calcium carbonate; calcium hydroxide; aluminum hydroxide; Magnesium, tribasic magnesium phosphate, zirconium silicate, synthetic resin-based abrasives and the like can be mentioned. Examples of the thickener include sodium carboxymethyl cellulose, carrageenan, sodium hydroxyethyl cellulose, sodium alginate, propylene glycol alginate, xanthan gum, polyacrylic acid, sodium polyacrylate, tara gum, guar gum, locust bean gum, hydroxyethyl cellulose, hydroxypropyl cellulose, Examples include methylcellulose, gellan gum, gelatin, curdlan, gum arabic, agar, pectin, polyvinyl alcohol, polyvinylpyrrolidone, pullulan and the like. [0007] Examples of the surfactant include an anionic surfactant, a cationic surfactant, a nonionic surfactant and the like. Specifically, sodium lauryl sulfate, α
-Sodium olefin sulfonate, N-acyl glutamate, 2-alkyl-N-carboxymethyl-N-hydroxyethyl imidazolinium betaine, N-acyl taurate, sucrose fatty acid ester, alkylol amide, polyoxyethylene hydrogenated castor oil , Polyglycerin fatty acid ester, pluronic, polyoxyethylene sorbitan monostearate and the like. Examples of the sweetener include saccharin sodium, stevioside, stevia extract, paramethoxycinnamic aldehyde, neohespyridyl hydrochalcone, and perillartin. Examples of the flavor include terpenes such as 1-menthol, carvone, anethole, limonene, and derivatives thereof. Examples of the coloring agent include Blue No. 1, Yellow No. 4, and titanium dioxide. In addition, as an active ingredient,
Cationic fungicides such as chlorhexidine, benzethonium chloride, benzalkonium chloride, cetylpyridinium chloride, decanium chloride; phenolic compounds such as triclosan, hinokitiol, and biosol, dextranase, mutanase, lysozyme amylase, protease, lytic enzyme, Enzymes such as superoxide dismutase; Vitamin E, Vitamin C
Vitamins such as: sodium monofluorophosphate, alkali metal monofluorophosphate such as calcium monofluorophosphate; fluorides such as sodium fluoride and stannous fluoride; tranexamic acid, epsilon aminocaproic acid, aluminum chlorohydroxyl Known active ingredients such as allantoin, dihydrocholesterol, glycyrrhizic acid, glycyrrhetinic acid, bisabolol, glycerophosphate, chlorophyll, sodium chloride, and a water-soluble inorganic phosphate compound are exemplified. [0008] The oral composition of the present invention includes various products applied to the oral cavity. Such products include:
Toothpaste, liquid toothpaste, mouthwash, mouth freshener, chewing gum and the like. The oral composition of the present invention contains a copolymer of vinylpyrrolidone and vinyl acetate, has a high plaque inhibitory effect, and has a high commercial value. Hereinafter, the present invention will be described specifically with reference to experimental examples and examples, but the present invention is not limited to the following examples. In addition,% in each example shows weight%. Example 1 1 ml of a solution obtained by extracting a test dentifrice having a component composition (% by weight) shown in Table 1 with three times the amount of water was dissolved in 4 ml of a 1% sucrose-added Brainheart infusion medium, and this was dissolved. After placing in a test tube and inoculating Streptococcus mutans bacteria that had been anaerobically cultured in advance, the cells were anaerobically cultured in a gradient medium for 18 hours, and the amount of bacteria attached to the test tube wall was measured. Also,
The same experiment was performed using a medium to which 1 ml of water was added instead of the toothpaste extract as a control. From the amount of adherent bacteria (XO) in the control and the amount of adherent bacteria using the test toothpaste (XS), the plaque formation inhibition rate was determined by the following formula. R = [(XS)-(XO)] / (XO) × 100 R: Inhibition rate of plaque formation (%) XS: Bacterial load using test toothpaste XO: Bacterial load in control [Table 1] The Luviskol V shown in the table
A64E is a vinylpyrrolidone / vinyl acetate copolymer manufactured by BASF [vinylpyrrolidone / vinyl acetate molar ratio = 60/40, weight average molecular weight of 60,000 to 70,0.
00]. As a result of the above experiment, a plaque formation inhibition rate of 23.8% was obtained in the control experiment, whereas the experiment using the test dentifrice extract containing the vinylpyrrolidone / vinyl acetate copolymer according to the present invention was performed in the control experiment. , A plaque formation inhibition rate of 88.5% was obtained. These results indicate that the composition of the present invention is effective in inhibiting plaque formation. Examples 2 to 14 Examples of specific compositions (% by weight) of the present invention are shown below. [Table 2] Example 10 (Junsei toothpaste) Luviskol VA64E 0.5 (wt%) Sodium pyrophosphate 3.0 Butylparaben 0.02 Calcium carbonate 70 Sorbitol 2 Glycerin 8 Sodium saccharin 0.08 Sodium lauryl sulfate 2.0 Purified water Remaining Example 11 (Mouthwash) Luviskol VA64E 1.0 (wt%) Sodium pyrophosphate 5.0 Ethanol 10.0 Glycerin 8.0 Saccharin sodium 0.1 Polyoxyethylene hydrogenated castor oil 1.0 Benzoic acid Sodium 0.3 Perfume 0.5 Purified water Remaining Example 12 (Mouthwash) Luviskol VA64E 2.0 (wt%) Aluminum lactate 0.5 Ethanol 5.0 Sorbitol 10.0 Saccharin sodium 1 Pluronic F127 2.0 Sodium Benzoate 0.3 Sodium Citrate 0.5 Perfume 0.4 Purified Water Remaining Example 13 (Mouthwash) Luviskol VA64E 1.0 (wt%) Antrine 0.5 Ethanol 8.0 Glycerin 12.0 Saccharin sodium 0.1 Polyoxyethylene hydrogenated castor oil 1.2 Sodium benzoate 0.3 Perfume 0.5 Purified water Remaining Example 14 (Mouth freshener) Luviskol VA64E 0.8 (Wt%) Sodium pyrophosphate 2.0 Ethanol 30.0 Glycerin 15.0 Saccharin sodium 0.3 Polyoxyethylene hydrogenated castor oil 3.0 Fragrance 1.0 Purified water Remaining

   ────────────────────────────────────────────────── ─── Continuation of front page    (72) Inventor Daisuke Uno             Rio, 1-3-7 Honjo, Sumida-ku, Tokyo             Inc. F-term (reference) 4C083 AB172 AB222 AB242 AB282                       AB292 AB322 AB472 AC102                       AC122 AC132 AC302 AC432                       AC482 AC642 AC662 AC682                       AC782 AC862 AD042 AD052                       AD091 AD092 AD272 AD352                       AD432 CC41 DD17 DD22                       DD23 EE36                 4J002 BF021 BJ001 FD010 FD090                       FD200 FD310 GB00

Claims (1)

Claims: 1. An oral composition comprising a copolymer of vinylpyrrolidone and vinyl acetate as a plaque formation inhibitor.